STK4 inhibitors for treatment of hematologic malignancies
申请人:Dana-Farber Cancer Institute, Inc.
公开号:US10710978B2
公开(公告)日:2020-07-14
The application relates to compounds of Formula (I′):
which modulate the activity of a kinase (e.g., STK4), a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease or disorder associated with the modulation of a kinase, such as STK4.
STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES
申请人:Dana-Farber Cancer Institute, Inc.
公开号:US20180111916A1
公开(公告)日:2018-04-26
The application relates to compounds of Formula (I′):
which modulate the activity of a kinase (e.g., STK4), a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease or disorder associated with the modulation of a kinase, such as STK4.
[EN] STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES<br/>[FR] INHIBITEURS STK4 POUR LE TRAITEMENT DE MALIGNITÉS HÉMATOLOGIQUES
申请人:DANA FARBER CANCER INST INC
公开号:WO2016161145A1
公开(公告)日:2016-10-06
The application relates to compounds of Formula (I'): which modulate the activity of a kinase (e.g., STK4), a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease or disorder associated with the modulation of a kinase, such as STK4.